Washington, D.C., USA, November 14, 2026
Novo Nordisk has announced positive primary results from its Phase 3 REDEFINE 9 clinical trial, evaluating lower doses of its investigational obesity treatment CagriSema, a fixed-dose combination of the long-acting amylin analogue cagrilintide and the GLP-1 receptor agonist semaglutide. The findings were presented at ObesityWeek 2026 in Washington, D.C., and simultaneously published in The Lancet Diabetes & Endocrinology. The study evaluated CagriSema at two lower-dose combinations, 1.7 mg/1.7 mg and 1.0 mg/1.0 mg, in adults living with overweight or obesity. After 68 weeks of treatment, participants receiving the two combinations achieved estimated average weight reductions of 20.7% and 21.0%, respectively, compared with 2.0% among participants receiving placebo, based on the efficacy estimand. These results represent an important development in obesity drug research because REDEFINE 9 is the first Phase 3 weight-management trial to investigate CagriSema at doses below the maximum 2.4 mg/2.4 mg previously evaluated in the REDEFINE clinical programme. The findings add to Novo Nordisk’s growing clinical evidence for combination-based metabolic treatments and provide further information about the potential of lower-dose regimens.
Phase 3 REDEFINE 9 Trial Demonstrates Significant Weight Loss
The REDEFINE 9 Phase 3 trial was designed to evaluate the efficacy and safety of lower-dose CagriSema in adults with overweight or obesity. The study compared two dose combinations against placebo over a 68-week treatment period. Participants received either CagriSema 1.7 mg/1.7 mg, CagriSema 1.0 mg/1.0 mg or placebo. The primary results demonstrated estimated average body-weight reductions of 20.7% with the 1.7 mg combination and 21.0% with the 1.0 mg combination, compared with 2.0% for placebo, assuming participants remained on treatment. Both combinations achieved statistically significant improvements over placebo, with p-values below 0.0001. The results also demonstrated that a significantly greater proportion of participants receiving CagriSema achieved clinically meaningful weight-loss thresholds. Approximately 95.1% and 96.3% of participants achieved at least 5% weight reduction with the two respective combinations, compared with 33.4% receiving placebo. Furthermore, 51.3% and 48.3% of participants achieved at least 20% weight reduction, compared with 2.7% in the placebo group. The trial also demonstrated improvements in waist circumference, with reductions of 17.2 cm and 17.5 cm, respectively, compared with 3.6 cm for placebo. Importantly, the study was not designed or powered to establish differences in effectiveness between the two CagriSema doses.
Combination of GLP-1 and Amylin Targets Obesity
CagriSema combines two complementary mechanisms of action to support weight management. Semaglutide is a GLP-1 receptor agonist that helps regulate appetite, food intake and blood glucose levels, while cagrilintide is a long-acting amylin analogue designed to influence appetite regulation and satiety. By combining these two biological pathways, the investigational treatment aims to provide greater weight-management benefits than targeting either pathway alone. The REDEFINE 9 findings showed that both lower-dose combinations produced substantial reductions in body weight and abdominal fat. Under the treatment-regimen estimand, which accounts for treatment discontinuation and the use of rescue interventions, estimated average weight reductions were 19.4% with the 1.7 mg/1.7 mg combination and 18.6% with the 1.0 mg/1.0 mg combination, compared with 4.6% for placebo. These results provide additional information about the treatment’s performance under conditions that more closely reflect the overall treatment experience. The findings could help inform future research into personalised obesity treatment strategies and dose selection based on individual patient needs and clinical judgement.
Safety Results and Future Regulatory Development
The safety profile observed in REDEFINE 9 was consistent with findings from previous CagriSema clinical studies. The most frequently reported adverse events were gastrointestinal reactions, which were generally mild to moderate in severity. Permanent treatment discontinuation due to adverse events occurred in 2.9% of participants receiving the 1.7 mg/1.7 mg combination and 4.9% receiving the 1.0 mg/1.0 mg combination, compared with 4.9% in the placebo group. Novo Nordisk continues to evaluate CagriSema through its broader clinical development programme to establish its efficacy and safety across different patient populations and dosing strategies. The company previously submitted a New Drug Application to the U.S. Food and Drug Administration (FDA) in December 2025 for CagriSema 2.4 mg/2.4 mg for weight management, with a regulatory decision expected in the fourth quarter of 2026. The lower-dose REDEFINE 9 findings provide additional clinical evidence for the investigational combination but do not represent a separate regulatory approval. CagriSema remains investigational and is not approved for weight management in the United States. The latest results highlight Novo Nordisk’s continued investment in obesity research and its efforts to develop differentiated combination therapies for people living with overweight and obesity.
Source: Novo Nordisk press release



